<DOC>
	<DOC>NCT02303002</DOC>
	<brief_summary>This is a safety and efficacy study of botulinum toxin type A in subjects with glabellar frown lines.</brief_summary>
	<brief_title>Efficacy and Safety of Botulinum Toxin Type A for Injection to Treat Glabellar Lines</brief_title>
	<detailed_description />
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Moderate or severe glabellar frown lines Female or male, 30 to 65 years of age in good general health Women of childbearing potential must agree to use an effective method of birth control during the course of the study Willing to refrain from receipt of facial fillers, laser treatments or use of products that affect skin remodeling and causes an active dermal response Any neurological condition that may place the subject at increased risk with exposure to Botulinum Toxin Type A such as amyotrophic lateral sclerosis and motor neuropathy, LambertEaton syndrome, and myasthenia gravis Muscle weakness or paralysis, particularly in the treatment area Active skin disease or infections or irritation at the treatment area Facial asymmetry, deep dermal scarring, or inability to substantially lessen the glabellar frown lines by manually spreading them apart Treatment with Botulinum Toxin Type A in the face in the last 6 months or in the last 3 months anywhere in the body</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>